الفهرس 
In vitro activity of plazomicin among carbapenem resistant Enterobacteriaceae in Cairo University hospitals
AbstractOnly 14 pages are availabe for public view
 |  | from | 141 |  |  |
| | | from | 141 | | |
Abstract
Over the last 2 decades, carbapenem-resistant Enterobacteriaceae (CRE) have been disseminated worldwide and become a global threat. Infections with these multidrug resistant (MDR) strains have limited therapeutic options.Plazomicin is a new semisynthetic aminoglycoside that was approved by the US Food and Drug Administration (FDA) in June 2018. Unlike other aminoglycosides, It remains stable against commonly encountered aminoglycosides modifying enzymes (AMEs). This suggests that plazomicin can be used in the treatment of infections caused by MDR pathogens including CRE.This study aims to assess the in vitro activity of plazomicin against CRE isolates. And to detect different types of carbapenemases among these isolates. Over one year we collected 102CRE isolates from the different clinical samples delivered to the microbiology laboratory of Cairo University hospitals.The presence of carbapenemaseswas detected by modified carbapenem inactivationmethod (mCIM) and Multiplex PCRtests. Plazomicin susceptibility testing was done using E test. Among the 102 isolates, 97 (95%) isolateswere Klebsiella species. The most frequently detected carbapenemase geneswereblaNDM in 75 (73.5%) isolates, followed by blaOXA-48 in 57 (55.9%) andblaKPC in 16 (15.5%) isolates.Plazomicin was active against 32 (31.4%) isolates